On May 24, zoelli Pharmaceutical (300181) recently announced that Chen guofen, the shareholder of the company, reduced 284000 shares of the company by means of centralized bidding transaction. The price range of this reduction is 7.185-7.257 yuan / share, and the cash out is about 2.061 million yuan.
According to the announcement, Chen guofen held 1136027 shares of the company before the reduction, and 852020 shares after the reduction, accounting for 0.14% of the total share capital.
According to the company’s report for the first quarter of 2021, the net profit attributable to shareholders of Listed Companies in the first quarter of 2021 was 43795349.24 yuan, an increase of 300.98% over the same period of last year.
According to the data of digbei.com, zoelli pharmaceutical is based on the fermentation technology of medicinal fungi to produce modern biological traditional Chinese medicine products. At present, zoelli pharmaceutical is mainly engaged in the R & D, production and sales of medicinal fungi Wuling and bailing series products, Chinese medicine decoction pieces and Chinese medicine formula granules. Keji pharmaceutical, a joint-stock company, focuses on the innovative cell therapy of solid tumors and hematological malignancies.